Advertisement

Translational Stroke Research

, Volume 10, Issue 5, pp 522–533 | Cite as

Soluble Epoxide Hydrolase-Derived Linoleic Acid Oxylipins in Serum Are Associated with Periventricular White Matter Hyperintensities and Vascular Cognitive Impairment

  • Di Yu
  • Marie Hennebelle
  • Demetrios J. Sahlas
  • Joel Ramirez
  • Fuqiang Gao
  • Mario Masellis
  • Hugo Cogo-Moreira
  • Richard H. Swartz
  • Nathan Herrmann
  • Pak Cheung Chan
  • Jacqueline A. Pettersen
  • Donald T. Stuss
  • Sandra E. Black
  • Ameer Y. Taha
  • Walter SwardfagerEmail author
Original Article
  • 200 Downloads

Abstract

White matter hyperintensities (WMH) are presumed to indicate subcortical ischemic vascular disease but their underlying pathobiology remains incompletely understood. The soluble epoxide hydrolase (sEH) enzyme converts anti-inflammatory and vasoactive cytochrome p450-derived polyunsaturated fatty acid epoxides into their less active corresponding diol species. Under the hypothesis that the activity of sEH might be associated with subcortical ischemic vascular disease and vascular cognitive impairment, this study aimed to compare the relative abundance of sEH substrates and products in peripheral blood between patients with extensive WMH (discovered due to transient ischemic attack; n = 29) and healthy elderly with minimal WMH (n = 25). The concentration of 12,13-DiHOME (a sEH-derived linoleic acid metabolite), and the ratio of 12,13-DiHOME to its sEH substrate, 12,13-EpOME, were elevated in the extensive WMH group (F1,53 = 5.9, p = 0.019), as was the 9,10-DiHOME/9,10-EpOME ratio (F1,53 = 5.4, p = 0.024). The 12,13-DiHOME/12,13-EpOME ratio was associated with poorer performance on a composite score derived from tests of psychomotor processing speed, attention, and executive function (β = − 0.473, p = 0.001, adjusted r2 = 0.213), but not with a composite verbal memory score. In a mediation model, periventricular WMH (but not deep WMH), explained 37% of the effect of the 12,13-DiHOME/12,13-EpOME ratio on the speed/attention/executive function composite score (indirect effect = − 0.50, 95% bootstrap confidence interval [− 0.99, − 0.17] Z-score units). Serum oxylipin changes consistent with higher sEH activity were markers of vascular cognitive impairment, and this association was partly explained by injury to the periventricular subcortical white matter.

Keywords

Small vessel disease Vascular cognitive impairment Oxylipins Soluble epoxide hydrolase Linoleic acid 

Notes

Acknowledgements

WS gratefully acknowledges support from the Alzheimer’s Association (US) & Brain Canada, The Canadian Partnership for Stroke Recovery, Sunnybrook Health Sciences Centre Department of Psychiatry, Sunnybrook Research Institute Hurvitz Brain Sciences Program, the University of Toronto Department of Pharmacology & Toxicology, and the Centre for Collaborative Drug Research. RHS is grateful to acknowledge support from the Heart and Stroke Foundation New Investigator Award, the Ontario Brain Institute’s Ontario Neurodegenerative Disease Research Initiative (ONDRI), the Departments of Medicine at the University of Toronto and Sunnybrook Health Sciences Centre, the Canadian Partnership for Stroke Recovery, and partial support from the Brill Chair in Neurology at Sunnybrook (Chair holder SEB).

The authors would like to thank Dr. Alan Moody for his contributions to the study, including data collection. The authors would also like to thank Maisha Khan for her contributions to the study, including helping with the samples.

Dr. Yurika Otoki is thanked for her contributions to the oxylipin method development.

Funding

This study is funded by the Alzheimer’s Association (US) and Brain Canada (AARG501466). JR & SEB received financial and salary support from the Fondation Leducq, Canadian Institutes of Health Research (#125740 & #13129), Heart & Stroke Foundation Canadian Partnership for Stroke Recovery, Hurvitz Brain Sciences Research program at Sunnybrook Research Institute and the Linda C. Campbell Foundation. JR additionally received partial funding from the Canadian Vascular Network and the ONDRI. SEB received financial and salary support from the Sunnybrook Research Institute, Sunnybrook Health Sciences Centre Department of Medicine and the Brill Chair Neurology, University of Toronto.

Compliance with Ethical Standards

Conflict of Interest

DY declares that she has no conflict of interest.

HCM declares that he has no conflict of interest.

RHS declares grant and personnel funding from the Heart and Stroke Foundation, CIHR, Ontario Brain Institute, Sunnybrook Health Sciences Centre and the University of Toronto, Department of Medicine.

NH declares research support from Lundbeck and consultant fees from Astellas, Merck & Lilly.

PCC declares that he has no conflict of interest.

JP declares that she has no conflict of interest.

DTS declares that he has no conflict of interest. .

SEB declares institutional grants from Pfizer, GE Healthcare, Eli Lilly, Cognoptix, Biogen Idec, and personal honoraria from Novartis, Merck, Pfizer, Eli Lilly, and Medscape/Biogen.

AT declares that he has no conflict of interest.

WS declares that he has no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9:689–701.  https://doi.org/10.1016/S1474-4422(10)70104-6.CrossRefGoogle Scholar
  2. 2.
    Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol. 2013;12:483–97.  https://doi.org/10.1016/S1474-4422(13)70060-7.CrossRefGoogle Scholar
  3. 3.
    Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J Am Heart Assoc. 2015;4:001140.  https://doi.org/10.1161/JAHA.114.001140.CrossRefGoogle Scholar
  4. 4.
    Swardfager W, Hennebelle M, Yu D, Hammock BD, Levitt AJ, Hashimoto K, et al. Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target. Neurosci Biobehav Rev. 2018;87:56–66.  https://doi.org/10.1016/j.neubiorev.2018.01.010.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in our understanding of oxylipins derived from dietary PUFAs. Adv Nutr. 2015;6:513–40.  https://doi.org/10.3945/an.114.007732.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349–61.  https://doi.org/10.1038/nri2294.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Davis CM, Liu X, Alkayed NJ. Cytochrome P450 eicosanoids in cerebrovascular function and disease. Pharmacol Ther. 2017;179:31–46.  https://doi.org/10.1016/j.pharmthera.2017.05.004.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18:419–34.  https://doi.org/10.1038/nrn.2017.48.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Chen Y, Tian H, Yao E, Tian Y, Zhang H, Xu L, et al. Soluble epoxide hydrolase inhibition promotes white matter integrity and long-term functional recovery after chronic hypoperfusion in mice. Sci Rep. 2017;7:7758.  https://doi.org/10.1038/s41598-017-08227-z.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Hu J, Dziumbla S, Lin J, Bibli S-I, Zukunft S, de Mos J, et al. Inhibition of soluble epoxide hydrolase prevents diabetic retinopathy. Nature. 2017;552:248–52.  https://doi.org/10.1038/nature25013.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Moghaddam MF, Grant DF, Cheek JM, Greene JF, Williamson KC, Hammock BD. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med. 1997;3:562–6.CrossRefGoogle Scholar
  12. 12.
    Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology. 2002;143:2376–84.  https://doi.org/10.1210/endo.143.6.8834.CrossRefGoogle Scholar
  13. 13.
    Sisemore MF, Zheng J, Yang JC, Thompson DA, Plopper CG, Cortopassi GA, et al. Cellular characterization of leukotoxin diol-induced mitochondrial dysfunction. Arch Biochem Biophys. 2001;392:32–7.  https://doi.org/10.1006/abbi.2001.2434.CrossRefGoogle Scholar
  14. 14.
    Viswanathan S, Hammock BD, Newman JW, Meerarani P, Toborek M, Hennig B. Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J Am Coll Nutr. 2003;22:502–10.CrossRefGoogle Scholar
  15. 15.
    Chang L-H, Lin H-C, Huang S-S, Chen I-C, Chu K-W, Chih C-L, et al. Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation. Sci Rep. 2018;8:118.  https://doi.org/10.1038/s41598-017-18558-6.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Nelson JW, Young JM, Borkar RN, Woltjer RL, Quinn JF, Silbert LC, et al. Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins Other Lipid Mediat. 2014;113–115:30–7.  https://doi.org/10.1016/j.prostaglandins.2014.09.003.CrossRefGoogle Scholar
  17. 17.
    Fazekas F, Chawluk J, Alavi A, Hurtig H, Zimmerman R. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Roentgenol. 1987;149:351–6.  https://doi.org/10.2214/ajr.149.2.351.CrossRefGoogle Scholar
  18. 18.
    Obinata H, Hattori T, Nakane S, Tatei K, Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem. 2005;280:40676–83.  https://doi.org/10.1074/jbc.M507787200.CrossRefGoogle Scholar
  19. 19.
    Hennebelle M, Otoki Y, Yang J, Hammock BD, Levitt AJ, Taha AY, et al. Altered soluble epoxide hydrolase-derived oxylipins in patients with seasonal major depression: an exploratory study. Psychiatry Res. 2017;252:94–101.  https://doi.org/10.1016/j.psychres.2017.02.056.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Yang J, Schmelzer K, Georgi K, Hammock BD. Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. Anal Chem. 2009;81:8085–93.  https://doi.org/10.1021/ac901282n.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Gibson E, Gao F, Black SE, Lobaugh NJ. Automatic segmentation of white matter hyperintensities in the elderly using FLAIR images at 3T. J Magn Reson Imaging. 2010;31:1311–22.  https://doi.org/10.1002/jmri.22004.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Ramirez J, Gibson E, Quddus A, Lobaugh NJ, Feinstein A, Levine B, et al. Lesion explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. NeuroImage. 2011;54:963–73.  https://doi.org/10.1016/j.neuroimage.2010.09.013.CrossRefGoogle Scholar
  23. 23.
    Ramirez J, Scott CJ, Black SE. A short-term scan-rescan reliability test measuring brain tissue and subcortical hyperintensity volumetrics obtained using the lesion explorer structural MRI processing pipeline. Brain Topogr. 2013;26(1):35–8.  https://doi.org/10.1007/s10548-012-0228-z.CrossRefGoogle Scholar
  24. 24.
    Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220–41.  https://doi.org/10.1161/01.STR.0000237236.88823.47.CrossRefGoogle Scholar
  25. 25.
    Ulu A, Davis BB, Tsai H-J, Kim I-H, Morisseau C, Inceoglu B, et al. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol. 2008;52:314–23.  https://doi.org/10.1097/FJC.0b013e318185fa3c.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Hanif A, Edin ML, Zeldin DC, Morisseau C, Nayeem MA. Effect of soluble epoxide hydrolase on the modulation of coronary reactive hyperemia: role of oxylipins and PPARγ. PLoS One. 2016;11(9):e0162147.  https://doi.org/10.1371/journal.pone.0162147.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput. 2004;36:717–31.CrossRefGoogle Scholar
  28. 28.
    Sura P, Sura R, Enayetallah AE, Grant DF. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem. 2008;56:551–9.  https://doi.org/10.1369/jhc.2008.950659.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Hennebelle M, Zhang Z, Metherel AH, Kitson AP, Otoki Y, Richardson CE, et al. Linoleic acid participates in the response to ischemic brain injury through oxidized metabolites that regulate neurotransmission. Sci Rep. 2017;7:4342.  https://doi.org/10.1038/s41598-017-02914-7.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Santiago C, Herrmann N, Swardfager W, Saleem M, Oh PI, Black SE, et al. White matter microstructural integrity is associated with executive function and processing speed in older adults with coronary artery disease. Am J Geriatr Psychiatry. 2015;23:754–63.  https://doi.org/10.1016/j.jagp.2014.09.008.CrossRefGoogle Scholar
  31. 31.
    Swardfager W, Cogo-Moreira H, Masellis M, Ramirez J, Herrmann N, Edwards JD, et al. The effect of white matter hyperintensities on verbal memory. Neurology. 2018;90:e673–e82.  https://doi.org/10.1212/WNL.0000000000004983.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Shinto L, Lahna D, Murchison CF, Dodge H, Hagen K, Quinn JF, et al. Plasma Omega-6 derived metabolite is associated with an “unfavorable” MRI profile and an Omega-3 derived metabolite is associated with a “favorable” MRI profile in a cohort of cognitively Normal hypertensive young-old. Alzheimers Dement. 2017;13:P1515–P6.  https://doi.org/10.1016/j.jalz.2017.07.636.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Di Yu
    • 1
    • 2
    • 3
    • 4
  • Marie Hennebelle
    • 5
  • Demetrios J. Sahlas
    • 6
  • Joel Ramirez
    • 1
  • Fuqiang Gao
    • 1
  • Mario Masellis
    • 1
    • 7
  • Hugo Cogo-Moreira
    • 8
    • 9
  • Richard H. Swartz
    • 1
    • 7
  • Nathan Herrmann
    • 1
  • Pak Cheung Chan
    • 10
    • 11
  • Jacqueline A. Pettersen
    • 12
  • Donald T. Stuss
    • 1
    • 7
    • 13
  • Sandra E. Black
    • 1
    • 3
    • 4
    • 7
  • Ameer Y. Taha
    • 5
  • Walter Swardfager
    • 1
    • 2
    • 3
    • 4
    • 14
    Email author
  1. 1.Hurvitz Brain Sciences ProgramSunnybrook Research InstituteTorontoCanada
  2. 2.Department of Pharmacology & ToxicologyUniversity of TorontoTorontoCanada
  3. 3.Canadian Partnership for Stroke RecoverySunnybrook Research InstituteTorontoCanada
  4. 4.LC Campbell Cognitive Neurology UnitSunnybrook Research InstituteTorontoCanada
  5. 5.Department of Food Science and Technology, College of Agriculture and Environmental SciencesUniversity of CaliforniaDavisUSA
  6. 6.Department of Medicine (Neurology Division)McMaster UniversityHamiltonCanada
  7. 7.Department of Medicine (Neurology Division)University of TorontoTorontoCanada
  8. 8.Departamento PsiquiatriaUniversidade Federal de São PauloSão PauloBrazil
  9. 9.Department of Education and Psychology: Division of Methods and EvaluationFreie Universität BerlinBerlinGermany
  10. 10.Department of Laboratory Medicine and PathobiologyUniversity of TorontoTorontoCanada
  11. 11.Department of Laboratory Medicine and Molecular DiagnosticsSunnybrook Health Sciences CentreTorontoCanada
  12. 12.Department of Medicine (Neurology Division) and the Northern Medical ProgramUniversity of British ColumbiaVancouverCanada
  13. 13.Department of PsychologyUniversity of TorontoTorontoCanada
  14. 14.University Health Network Toronto Rehabilitation InstituteTorontoCanada

Personalised recommendations